Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
The decision will largely prevent compounding pharmacies from making and selling compounded versions of the drug in the next ...
Zepbound, a popular weight loss drug, has become the first FDA-approved prescription medication to treat obstructive sleep ...
The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...
The Food and Drug Administration on Friday approved Eli Lilly’s weight-loss drug Zepbound to treat sleep apnea, a common but ...
The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).
Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound to treat ...
On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand version in early 2025 Charlotte Phillipp is a Weekend Writer-Reporter at ...
The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.
Eli Lilly’s weight loss drug Zepbound is no longer in short supply, the FDA said, worrying patients who use cheaper, off-brand versions of the drug. On Thursday, Dec. 19, the U.S. Food and Drug ...